NCT07208461View on ClinicalTrials.gov

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Respiratory Syncytial Virus Infection Prevention
Interventions
BIOLOGICAL

Low dose antigen of LYB005 without A01B adjuvant

0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.

BIOLOGICAL

Low dose antigen of LYB005 with A01B adjuvant

0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.

BIOLOGICAL

Middle dose antigen of LYB005 without A01B adjuvant

0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.

BIOLOGICAL

Middle dose antigen of LYB005 with A01B adjuvant

0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.

BIOLOGICAL

High dose antigen of LYB005 without A01B adjuvant

0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.

BIOLOGICAL

High dose antigen of LYB005 with A01B adjuvant

0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.

BIOLOGICAL

Placebo

0.5 mL 0.9% sodium chloride (normal saline) injection per dose

Trial Locations (1)

Unknown

Center for Disease Control and Prevention of Dangyang City, Dangyang

All Listed Sponsors
lead

Guangzhou Patronus Biotech Co., Ltd.

INDUSTRY